3 ms·
New Vaccines Prevent Ebola and Marburg in Monkeys (2005)
- denzil_correa 12y agoThe vaccine did not take off and sat of the shelf because Ebola was "rare". It would have been ready for licensing by 2010-11. http://nytimes.com/2014/10/24/health/without-lucrative-market-potential-ebola-vaccine-was-shelved-for-years.html?referrer=&_r=2 http://nytimes.com/2014/10/24/health/without-lucrative-marke...
- ams6110 12y agoEbola was (and still is, compared to e.g. malaria) rare, no scare quotes needed. Until the latest outbreak in west Africa, Ebola infections were limited to handfuls of people. Not surprising that the developers of this vaccine did not take it through the gauntlet of expensive approvals, clinical trials, etc. that would be required to get it on the market.
- hga 12y agoNot quite "handfuls", but the official outbreak numbers for the Zaire strain, the one causing the current epidemic, never went higher than 318. It should be noted that clinical trials for vaccines are the most rigorous, because they are for healthy people.
- icecreampain 12y agoConsidering the effects of the various "vaccines" we've seen recently - I think we're better off not letting the state inject us with things we don't know about, yes?
- hga 12y agoIn partial response to a dead comment, this vaccine is "known" and at least in theory is likely to be safe. It takes an existing, well understood virus that mostly affects animals. From memory, it knocks out one gene that makes it pathogenic, and adds (or replaces?) genes to express surface Ebola virus surface proteins.